Anthracycline treatment is associated with an increased risk of heart failure.
Is it true that Anthracycline treatment is associated with an increased risk of heart failure?
Yes. Extensive clinical and experimental evidence demonstrates that anthracycline treatment is strongly associated with an increased risk of cardiotoxicity and subsequent heart failure.
Verdict: SUPPORTED · 7 sources for, 0 against · Last checked
The retrieved literature unanimously and consistently supports the association between anthracyclines (such as doxorubicin) and an increased risk of cardiotoxicity, cardiomyopathy, and heart failure. Multiple reviews and experimental studies document this well-established clinical adverse effect.
Get citation
Sobczuk, P., Czerwińska, M., Kleibert, M., & Cudnoch-Jędrzejewska, A. (2020). Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system—from molecular mechanisms to therapeutic applications. doi.org. https://doi.org/10.1007/s10741-020-09977-1
See more details
Get citation
C, G., D, P., I, J., V, B., A, A., C, P., A, d. M., L, C., D, M., C, C., GJ, L., J, V., J, O., V, F., J, S., & B, I. (2026). Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.. doi.org. https://doi.org/10.1093/eurheartj/ehaf1060
Get citation
Z, M., N, A., AJ, H., R, I., & M, A. (2026). Reassessing the Role of Anthracyclines in Early HER2-Positive Breast Cancer in the Era of HER2-Targeted Therapy and Treatment De-Escalation: A Systematic Review and Narrative Synthesis.. doi.org. https://doi.org/10.3390/jcm15187303
Get citation
TG, B., YK, T., AJ, E., & JR, M. (2026). Understanding the distinct role of PI3K(p110<i>α</i>) in cancer and the heart to prevent chemotherapy-induced cardiotoxicity: mechanisms and therapeutic opportunities.. doi.org. https://doi.org/10.3389/fcvm.2026.1891148
Get citation
Bhagat, A. & Kleinerman, E. S. (2020). Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention.. doi.org. https://doi.org/10.1007/978-3-030-43032-0_15
Get citation
Wu, L., Wang, L., Du, Y., Zhang, Y., & Ren, J. (2023). Mitochondrial quality control mechanisms as therapeutic targets in doxorubicin-induced cardiotoxicity.. doi.org. https://doi.org/10.1016/j.tips.2022.10.003
Get citation
Sheibani, M., Azizi, Y., Shayan, M., Nezamoleslami, S., Eslami, F., Farjoo, M. H., & Dehpour, A. R. (2022). Doxorubicin-Induced Cardiotoxicity: An Overview on Pre-clinical Therapeutic Approaches.. doi.org. https://doi.org/10.1007/s12012-022-09721-1
What does the evidence say?
The retrieved literature unanimously and consistently supports the association between anthracyclines (such as doxorubicin) and an increased risk of cardiotoxicity, cardiomyopathy, and heart failure. Multiple reviews and experimental studies document this well-established clinical adverse effect.
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work